AbbVie (ABBV) Cash from Investing Activities (2012 - 2026)

AbbVie (ABBV) has reported Cash from Investing Activities for 15 consecutive years, with -$1.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 1.35% year-over-year to -$1.2 billion in Q2 2026; TTM through Jun 2026 was -$6.5 billion, a 46.06% increase from a year earlier, with the FY2025 full-year figure at -$6.6 billion, up 68.09% from the prior year.
• Cash from Investing Activities was -$1.2 billion for Q2 2026 at AbbVie, down from -$574.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.3 billion in Q3 2022 and troughed at -$9.6 billion in Q1 2024.
• A 5-year average of -$1.8 billion and a median of -$951.0 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 309.11% in 2022 and tumbled 2137.4% in 2024, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$448.0 million in 2022, then plunged by 78.57% to -$800.0 million in 2023, then slumped by 134.25% to -$1.9 billion in 2024, then grew by 21.93% to -$1.5 billion in 2025, then advanced by 18.18% to -$1.2 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$1.2 billion (Q2 2026), -$574.0 million (Q1 2026), and -$1.5 billion (Q4 2025), per Business Quant data.